___

• Adler, R., Kelsey, N., Maik, M., & Song, J. H. (2021). Production of a SARS-CoV-2 Spike Protein Vaccine Using the Baculovirus Expression Vector System. Senior Design Reports (CBE). Erişim adresi: https://repository.upenn.edu/cbe_sdr/131
• Al-Barwani, F., Donaldson, B., Pelham, S. J. Young, S.L., & Ward, V.K. (2014) Antigen delivery by virus-like particles for immunotherapeutic vaccination. Ther Deliv 5:1223–1240. https://doi.org/10.4155/tde.14.74
• Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., ve diğerleri. (2021). Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. New England Journal of Medicine, 384(5), 403–416. https://doi.org/10.1056/nejmoa2035389
• Bancel, S., Issa, W. J., Aunins, J. G., & Chakraborty, T. (2014). Manufacturing Methods for Production of Rna Transcripts.
• Bangari, Dinesh S., & Suresh K. Mittal. (2006). “Development of Nonhuman Adenoviruses as Vaccine Vectors.” Vaccine 24(7):849–62. doi: 10.1016/j.vaccine.2005.08.101.
• Calina, D., Docea, A. O., Petrakis, D., Egorov, A. M., Ishmukhametov, A. A., Gabibov, A. G., ve diğerleri. (2020). Towards effective COVID-19 vaccines: Updates, perspectives and challenges (Review). International Journal of Molecular Medicine, 46(1), 3. https://doi.org/10.3892/IJMM.2020.4596
• Carlson, R., & Lutmer, H. (2021). EpiVacCorona Vaccine — Precision Vaccinations. Erişim adresi: https://www.precisionvaccinations.com/vaccines/epivaccorona-vaccine
• Centers for Disease Control and Prevention. (2020), Erişim adresi: https://www.cdc.gov/coronavirus/2019-ncov/hcp/therapeutic-options.html
• Chen, Q., Lai, H., Hurtado, J., ve diğerleri. (2013) Agroinfiltration as an Effective and Scalable Strategy of Gene Delivery for Production of Pharmaceutical Proteins. Adv Tech Biol Med 01:1–21. https://doi.org/10.4172/atbm.1000103
• Chen, W. H., Chag, S. M., Poongavanam, M. V., Biter, A. B., Ewere, E. A., Rezende, W., ve diğerleri. (2017). Optimization of the Production Process and Characterization of the Yeast-Expressed SARS-CoV Recombinant Receptor-Binding Domain (RBD219-N1), a SARS Vaccine Candidate. Journal of Pharmaceutical Sciences, 106(8), 1961–1970. https://doi.org/10.1016/J.XPHS.2017.04.037
• ClinicalTrials.gov. (2021). Study of a Recombinant Coronavirus-Like Particle COVID-19 Vaccine in Adults. Erişim adresi: https://clinicaltrials.gov/ct2/show/NCT04636697
• ClinicalTrials.gov. (2021). Study of the Tolerability, Safety, Immunogenicity and Preventive Efficacy of the EpiVacCorona Vaccine for the Prevention of COVID-19. Erişim adresi: https://clinicaltrials.gov/ct2/show/NCT04780035
• Coronavirus disease (COVID-19): Vaccines.WHO., What types of COVID-19 vaccines are being developed? How would they work? (2021). Erişim adresi: https://www.who.int/news-room/q-a-detail/coronavirus-disease-(covid-19)-vaccines?adgroupsurvey=%7Badgroupsurvey%7Dvegclid=CjwKCAjwjJmIBhA4EiwAQdCbxgEpRqmN1zv1xwgjNghhEg9zGLvZdlf-wQX6AMrz87oGoZKl0jdTuBoCUUwQAvD_BwE
• Dai, L., & Gao, G. F. (2020). Viral targets for vaccines against COVID-19. Nature Reviews Immunology 2020 21:2, 21(2), 73–82. https://doi.org/10.1038/s41577-020-00480-0
• Dai, S., Wang, H., & Deng, F. (2018). Advances and challenges in enveloped virus-like particle (VLP)-based vaccines. Journal of Immunological Sciences, 2(2), 36–41. https://doi.org/10.29245/2578-3009/2018/2.1118
• Delrue, I., Verzele, D., Madder, A., & Nauwyck, H. J. (2012). Inactivated virus vaccines from chemistry to prophylaxis: Merits, risks and challenges. Expert Review of Vaccines, 11(6), 695–719. https://doi.org/10.1586/erv.12.38
• Edelstein, M., Scott, P. E., Sherlund, M., Hansen, A. L., & Hughes, J. L. (1986). Design Considerations for Pilot Scale Solid Phase Peptide Synthesis Reactors. Chemical Engineering Science, 41(4), 617–624.
• El Hajjami, N., Brantner, M. M., Boumlic, A., Mantri, S., & Cebi, B. (2021). Manufacturing Strategies for mRNA Vaccines and Therapeutics | Sigma-Aldrich. In Merck Technical Documents. Erişim adresi: https://www.sigmaaldrich.com/technical-documents/articles/white-papers/manufacturing-strategies-for-mrna-vaccines.html
• Ellis, R. W. (2001). MIU 26 MEDICAL INTELLIGENCE UNIT 26 New Vaccine Technologies (R. W. Ellis, Ed.). Eurekah.com / Landes Bioscience, 810 South Church Street. Erişim adresi: www.Eurekah.com
• Giese, M. (2016). Types of Recombinant Vaccines. Introduction to Molecular Vaccinology, 199–232. https://doi.org/10.1007/978-3-319-25832-4_9
• Giroux, D.D., Ramachandra, M., & Shabram, P. Viral production process. US5994134; (1999).
• Gopal, R. & Schneemann, A. (2018) Production and application of insect virus-based VLPs. Methods Mol Biol 1776:125–141. https://doi.org/10.1007/978-1-4939-7808-3_8
• Hartman, A. L., Cole, K. S., & Homer, L. C. (2012). Verification of Inactivation Methods for Removal of Biological Materials from a Biosafety Level 3 Select Agent Facility. Applied Biosafety, 17(2), 70–75. https://doi.org/10.1177/153567601201700204
• Heartlein, M., Derosa, F., Dıas, A., & Karve, S. (2014). Patent No. WO 2014/152966 Al. WIPO (PCT). Erişim adresi: https://patents.google.com/patent/WO2014152966A1/en#citedBy
• Hsieh, C., Goldsmith, J.A., Schaub, J.M., ve diğerleri. (2020) Structure-based design of prefusion-stabilized SARS-CoV-2 spikes. 0826:1–9
• Huang, Y., Yang, C., Xu, X., Xu, W., & Liu, S. (2020). Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19. Acta Pharmacologica Sinica 2020 41:9, 41(9), 1141–1149. https://doi.org/10.1038/s41401-020-0485-4
• Icosavax Initiates Phase 1/2 Trial of COVID-19 VLP Vaccine Candidate, 2021. Erişim adresi: https://investors.icosavax.com/news-releases/news-release-details/icosavax-initiates-phase-12-trial-covid-19-vlp-vaccine-candidate/
• Iversen, P. L., & Bavari, S. (2021). Inactivated COVID-19 vaccines to make a global impact. The Lancet Infectious Diseases, 21(6), 746–748. https://doi.org/10.1016/S1473-3099(21)00020-7
• Iyer, P., Ostrove, J. & Vacante, D. (1999). “Comparison of Manufacturing Techniques for Adenovirus Production.” Cytotechnology 30(1–3):169–72. doi: 10.1023/a:1008040221630.
• Jackson, N. A. C., Kester, K. E., Casimiro, D., Gurunathan, S., & Derosa, F. (2020). The promise of mRNA vaccines: a biotech and industrial perspective. Nature Partner Journals. https://doi.org/10.1038/s41541-020-0159-8
• Jeyanathan, M., Afkhami, S., Smaill, F., Miller, M. S., Lichty, B. D., & Xing, Z. (2020). Immunological considerations for COVID-19 vaccine strategies. Nature Reviews Immunology, 20(10), 615–632. https://doi.org/10.1038/S41577-020-00434-6
• Karandikar, S., Mirani, A., Waybhase, V., Patravale, V. B., & Patankar, S. (2017). Nanovaccines for oral delivery-formulation strategies and challenges. In Nanostructures for Oral Medicine (pp. 263–293). Elsevier. https://doi.org/10.1016/B978-0-323-47720-8.00011-0
• Kocagöz, S. (2017). Aşı Teknolojisi ve Aşı Tipleri.
• Kon, T. C., Onu, A., Berbecila, L., Lupulescu, E., Ghiorgisor, A., Kersten, G. F., ve diğerleri. (2016). Influenza vaccine manufacturing: Effect of inactivation, splitting and site of manufacturing. Comparison of influenza vaccine production processes. PLoS ONE, 11(3), 1–19. https://doi.org/10.1371/journal.pone.0150700
• Kowalzik, F., Schreiner, D., Jensen, C., Teschner, D., Gehring, S., & Zepp, F. (2021). mRNA-Based Vaccines. Vaccines, 9(390), 1–15.
• Kwon, H., Kim, M., Seo, Y., Moon, Y. S., Lee, H. J., Lee, K., & Lee, H. (2018). Emergence of synthetic mRNA: In vitro synthesis of mRNA and its applications in regenerative medicine. Biomaterials, 156, 172–193. https://doi.org/10.1016/j.biomaterials.2017.11.034
• Kyriakidis, N. C., López-Cortés, A., González, E. V., Grimaldos, A. B., & Prado, E. O. (2021). SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates. Npj Vaccines 2021 6:1, 6(1), 1–17. https://doi.org/10.1038/s41541-021-00292-w
• Li, W., Joshi, M. D., Singhania, S., Ramsey, K. H., & Murthy, A. K. (2014). Peptide vaccine: Progress and challenges. Vaccines, Vol. 2, pp. 515–536. MDPI AG. https://doi.org/10.3390/vaccines2030515
• Liang, Z., Zhu, H., Wang, X., Jing, B., Li, Z., Xia, X., ve diğerleri. (2020). Adjuvants for Coronavirus Vaccines. Frontiers in Immunology, 11(November). https://doi.org/10.3389/fimmu.2020.589833
• Lusky, M. (2005). “Good Manufacturing Practices Production of Adenoviral Vectors for Clinical Trials.” Human Gene Therapy 291(March):281–91.
• Lodish, H., Berk, A., Zipursky, S.L., Matsudaira, P., Baltimore, D. & Darnell, J. (2010). Molecular Cell Biology. In Fourth Edition, W. H. Freeman.
• MacLachlan, J. N., & Dubovi, E. J. (2011). Fenner’s Veterinary Virology. In Fourth Edition, Elsevier.
• Marcelino, I., Vachiéry, N., Amaral, A. I., Roldão, A., Lefrançois, T., Carrondo, M. J. T. ve diğerleri. (2007). Effect of the purification process and the storage conditions on the efficacy of an inactivated vaccine against heartwater. Vaccine, 25(26), 4903–4913. https://doi.org/10.1016/j.vaccine.2007.04.055
• Moisa, A. A., & Kolesanova, E. F. (2010). Synthetic peptide vaccines. Biochemistry (Moscow) Supplement Series B: Biomedical Chemistry, 4(4), 321–332. https://doi.org/10.1134/S1990750810040025
• Montagnon, B. J., Fanget, B., & Vincent-Falquet, J. C. (1984). Industrial-scale production of inactivated poliovirus vaccine prepared by culture of Vero cells on microcarrier. Reviews of Infectious Diseases, 6 Suppl 2(June), 0–3. https://doi.org/10.1093/clinids/6.supplement_2.s341
• Nascimento, I. P., & Leite, L. C. C. (2012). Recombinant vaccines and the development of new vaccine strategies. Brazilian Journal of Medical and Biological Research, 45(12), 1102. https://doi.org/10.1590/S0100-879X2012007500142
• Ndwandwe, D., & Wiysonge, C. S. (2021). COVID-19 vaccines. Current Opinion in Immunology, 71(Figure 1), 111–116. https://doi.org/10.1016/j.coi.2021.07.003
• Nooraei, S., Bahrulolum, H., Hoseini, Z.S., ve diğerleri. (2021) Virus-like particles: preparation, immunogenicity and their roles as nanovaccines and drug nanocarriers. J Nanobiotechnology 19:59. https://doi.org/10.1186/s12951-021-00806-7
• Novavax Publishes Results of United Kingdom Phase 3 Clinical Trial in New England Journal of Medicine, Demonstrating High Levels of Efficacy of COVID-19 Vaccine - Jun 30, 2021. (2021). Erişim tarihi ve adresi: 9 Ağustos 2021, https://ir.novavax.com/2021-06-30-Novavax-Publishes-Results-of-United-Kingdom-Phase-3-Clinical-Trial-in-New-England-Journal-of-Medicine,-Demonstrating-High-Levels-of-Efficacy-of-COVID-19-Vaccine
• Okyay, P. (2020). “Covid-19 Aşı Çalışmaları.” Türk Tabi̇pleri Bi̇rli̇ği̇ Covi̇d-19 Pandemi̇si̇ Altıncı Ay Değerlendi̇rme Raporu, 228–52.
• Özcan, Ö. Ö., Karahan, M., Vijayaraj Kumar, P., Leng Tan, S., & Na Tee, Y. (2020). New Generation Peptide-Based Vaccine Prototype. In Prototyping Technology (pp. 1–20). https://doi.org/10.5772/intechopen.89115
• Pardi, N., Hogan, M. J., Porter, F. W., & Weissman, D. (2018). mRNA vaccines-a new era in vaccinology. Nature Reviews Drug Discovery, 17(4), 261–279. https://doi.org/10.1038/nrd.2017.243
• Pelit Arayıcı, P., Acar, T., Karahan, M., & Mustafaeva, Z. (2016). Review Paper / Derleme Makalesi A New Approach For Development Of Synthetıc Peptide Vaccınes For Vıral Infectıons. Sigma J Eng ve Nat Sci, 7(2), 193–204.
• Peters, J. (2020). What are the advantages of an mRNA vaccine for COVID-19? Massive Science. Erişim adresi: https://massivesci.com/articles/mrna-vaccine-covid19-coronavirus-moderna/
• Philippidis, A. (2020). The Cold Truth about COVID-19 Vaccines. Erişim adresi: https://www.genengnews.com/news/the-cold-truth-about-covid-19-vaccines/
• Pino, P., Kint, J., Kiseljak, D., Agnolon, V., Corradin, G., Kajava, A. V., ve diğerleri (2020). Trimeric SARS-CoV-2 Spike Proteins Produced from CHO Cells in Bioreactors Are High-Quality Antigens. Processes 2020, Vol. 8, Page 1539, 8(12), 1539. https://doi.org/10.3390/PR8121539
• Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., ve diğerleri. (2020). Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. New England Journal of Medicine, 383(27), 2603–2615. https://doi.org/10.1056/nejmoa2034577
• Pollet, J., Chen, W. H., & Strych, U. (2021a). Recombinant protein vaccines, a proven approach against coronavirus pandemics. Advanced Drug Delivery Reviews, 170, 71. https://doi.org/10.1016/J.ADDR.2021.01.001
• Roldão, A., Mellado, M. C. M., Castilho, L. R., Carrondo, M. J., & Alves, P. M. (2010). Virus-like particles in vaccine development. Expert Review of Vaccines, 9(10), 1149–1176. https://doi.org/10.1586/erv.10.115
• Rowe, P.W., Ruebner, H. J., Gilmore, L. K., Parrott R.H., & Ward T. K. (1953). Isolation of a Cytopathogenic Agent from Human Adenoids Undergoing Spontaneous Degeneration in Tissue Culture. Proceedings of the Society for Experimental Biology and Medicine, 84(3):570-573. doi:10.3181/00379727-84-20714
• Sabbaghi, A., Miri, S. M., Keshavarz, M., Zargar, M., & Ghaemi, A. (2019). Inactivation methods for whole influenza vaccine production. Reviews in Medical Virology, 29(6), 1–11. https://doi.org/10.1002/rmv.2074
• Sapsford, K.E., Algar, W.R., Berti, L., ve diğerleri. (2013) Functionalizing Nanoparticles with Biological Molecules: Developing Chemistries that Facilitate Nanotechnology. Chem Rev 113:1904–2074. https://doi.org/10.1021/cr300143v SCB-2019 as COVID-19 Vaccine (NCT number): NCT04405908. (2021). 11 Ağustos 2021 tarihinde ClinicalTrials.gov’dan erişilmiştir. Erişim adresi: https://clinicaltrials.gov/ct2/show/NCT04405908
• Schoenmaker, L., Witzigmann, D., Kulkarni, J. A., Verbeke, R., Kersten, G., Jiskoot, W., & Crommelin, D. J. A. (2021). mRNA-lipid nanoparticle COVID-19 vaccines: Structure and stability. International Journal of Pharmaceutics, 601, 120586. https://doi.org/10.1016/j.ijpharm.2021.120586
• Sesardic, D. (1993). Synthetic peptide vaccines. Medical Microbiology, 39, 241–242.
• Singh, S., Kumar, R., & Agrawal, B. (2019). Chapter 4 Adenoviral Vector-Based Vaccines and Gene Therapies : Current Status and Future Prospects.
• Skwarczynski, M., & Toth, I. (2016). Peptide-based synthetic vaccines. Chemical Science, 7(2), 842–854. https://doi.org/10.1039/c5sc03892h
• Smith, M.T., Hawes, A.K., & Bundy, B.C. (2013) Reengineering viruses and virus-like particles through chemical functionalization strategies. Curr Opin Biotechnol 24:620–626. https://doi.org/10.1016/j.copbio.2013.01.011
• Soler, E., & Houdebine, L. M. (2007). Preparation of recombinant vaccines. Biotechnology Annual Review, 13, 65–94. https://doi.org/10.1016/S1387-2656(07)13004-0 SpyBiotech and Serum Institute of India announce that the first subjects have been dosed in a Phase I/II trial of a novel virus-like particle vaccine targeting COVID-19. (2020, September 8). Erişim adresi: https://www.spybiotech.com/news/-/ Status of COVID-19 Vaccines within WHO EUL/PQ. (2021).
• Stuible, M., Gervais, C., Lord-Dufour, S., Perret, S., L’Abbé, D., Schrag, J., ve diğerleri. (2021). Rapid, high-yield production of full-length SARS-CoV-2 spike ectodomain by transient gene expression in CHO cells. Journal of Biotechnology, 326, 21. https://doi.org/10.1016/J.JBIOTEC.2020.12.005
• Tagliamonte, M., Tornesello, M.L., Buonaguro, F. M., & Buonaguro, L. (2017) Virus-Like Particles. In: Micro and Nanotechnology in Vaccine Development. Elsevier, pp 205–219
• Tan, T.K., Rijal, P., Rahikainen, R., ve diğerleri. (2021) A COVID-19 vaccine candidate using SpyCatcher multimerization of the SARS-CoV-2 spike protein receptor-binding domain induces potent neutralising antibody responses. Nat Commun 12:542. https://doi.org/10.1038/s41467-020-20654-7
• Tanriover, M. D., Doğanay, H. L., Akova, M., Güner, H. R., Azap, A., Akhan, S., ve diğerleri (2021). Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey. The Lancet, 398(10296), 213–222. https://doi.org/10.1016/S0140-6736(21)01429-X
• Tatsis, N., & Ertl, H.C.J. (2004). “Adenoviruses as Vaccine Vectors.” Molecular Therapy 10(4):616–29. doi: 10.1016/j.ymthe.2004.07.013.
• Terkis, S., Pavel, I., Yetiskin, H., Aydin, G., Id, C. H., Uygut, M. A., ve diğerleri. (2020). Isolation and characterization of severe acute respiratory syndrome coronavirus 2 in Turkey. 1–17. https://doi.org/10.1371/journal.pone.0238614
• Thomassen, Y. E., van ’t Oever, A. G., Vinke, M., Spiekstra, A., Wijffels, R. H., van der Pol, L. A., & Bakker, W. A. M. (2013). Scale-down of the inactivated polio vaccine production process. Biotechnology and Bioengineering, 110(5), 1354–1365. https://doi.org/10.1002/bit.24798
• Thrane, S., Janitzek, C.M., Matondo, S., ve diğerleri. (2016). Bacterial superglue enables easy development of efficient virus-like particle based vaccines. J Nanobiotechnology 14:30. https://doi.org/10.1186/s12951-016-0181-1
• Tian, J.H., Patel, N., Haupt, R., ve diğerleri. (2021). SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice. Nat Commun 12: https://doi.org/10.1038/s41467-020-20653-8
• Topuzoğulları, M., Acar, T., Pelit Arayici, P., Uçar, B., Uğurel, E., Abamor, E. Ş., Arasoğlu, T., Turgut-Balik, D., & Derman, S. (2020). An insight into the epitope-based peptide vaccine design strategy and studies against COVID-19. Turkish journal of biology = Turk biyoloji dergisi, 44(3), 215–227. https://doi.org/10.3906/biy-2006-1
• Toriniwa, H., & Komiya, T. 2007. Japanese encephalitis virus production in Vero cells with serum-free medium using a novel oscillating bioreactor. 1–6. https://doi.org/10.1016/j.biologicals.2007.02.002
• Tsao, Y.S., Condon, R., Schaefer, E., Lio, P., & Liu, Z. (2001). “Development and Improvement of a Serum-Free Suspension Process for the Production of Recombinant Adenoviral Vectors Using HEK293 Cells.” Cytotechnology 37(3):189–98. doi: 10.1023/A:1020555310558.
• Turner, G. S., Squires, E. J., & Murray, H. G. S. 1970. Inactivated smallpox vaccine. A comparison of inactivation methods. Journal of Hygiene, 68(2), 197–210. https://doi.org/10.1017/S0022172400028679 van Riel, D., & de Wit, E. 2020. Next-generation vaccine platforms for COVID-19. Nature Materials (2020) 19:8, 19(8), 810–812. https://doi.org/10.1038/s41563-020-0746-0
• Vannucci, L., Lai, M., Chiuppesi, F., Ceccherini-Nelli, L., ve Pistello, M. (2013). Viral vectors: A look back and ahead on gene transfer technology. New Microbiologica, 36(1), 1–22.
• Vemula, S.V., & Mittal, S.K. 2010. “Production of Adenovirus Vectors and Their Use as a Delivery System for Influenza Vaccines.” Expert Opinion on Biological Therapy 10(10):1469–87. doi: 10.1517/14712598.2010.519332.
• Verdecia, M., Kokai-Kun, J. F., Kibbey, M., Acharya, S., Venema, J., ve Atouf, F. (2021). COVID-19 vaccine platforms: Delivering on a promise? Human Vaccines and Immunotherapeutics, 00(00), 1–21. https://doi.org/10.1080/21645515.2021.1911204
• Walls, A.C., Fiala, B., Schäfer, A. ve diğerleri. (2020) Elicitation of Potent Neutralizing Antibody Responses by Designed Protein Nanoparticle Vaccines for SARS-CoV-2. Cell 183:1367-1382.e17. https://doi.org/10.1016/j.cell.2020.10.043
• Wang, F., Kream, R. M., & Stefano, G. B. (2020). An evidence based perspective on mRNA-SARScov-2 vaccine development. Medical Science Monitor, 26, 1–8. https://doi.org/10.12659/MSM.924700
• Wang, J., Peng, Y., Xu, H., Cui, Z., & Williams, R. O. (2020). The COVID-19 Vaccine Race: Challenges and Opportunities in Vaccine Formulation. AAPS PharmSciTech, 21(6), 1–12. https://doi.org/10.1208/s12249-020-01744-7
• Wikipedia, (2021). EpiVacCorona Definition Wikipedia. Erişim adresi: https://en.wikipedia.org/wiki/EpiVacCorona
• Wolff, J. A., Malone, R. W., Williams, P., Chong, W., Acsadi, G., Jani, A., & Felgner, P. L. (1990). Direct Gene Transfer into Mouse Muscle in Vivo. Science, 247(4949), 1465–1468.
• World Health Organization. (1999). Guidelines for the production and quality control of synthetic peptide vaccines.
• Xıaojuan, C., Chen Yan, Hou Ye, Lan Qın, Sı Huanhuan ve Song Chunyu. (2020). Patent No. CN112552413A. Taizhou Baike Biological Tech Co Ltd. Erişim adresi: https://worldwide.espacenet.com/patent/search/family/075031652/publication/CN112552413A?q=ti all %22recombinant%22 AND ta all %22protein%22 AND ta all %22vaccine%22 AND ta all %22cov%22
• Yadav, T., Srivastava, N., Mishra, G., Dhama, K., Kumar, S., Puri, B., & Saxena, S. K. (2020). Recombinant vaccines for COVID-19. Human Vaccines ve Immunotherapeutics, 16(12), 1. https://doi.org/10.1080/21645515.2020.1820808
• Yang, S., Li, Y., Dai, L., Wang, J., He, P., Li, C.,ve diğerleri. (2021). Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials. The Lancet. Infectious Diseases, 21(8), 1107. https://doi.org/10.1016/S1473-3099(21)00127-4
• Yilmaz, I. C., Ipekoglu, E., Bulbul, A., ve diğerleri. (2021). Development and Preclinical Evaluation of Virus Like Particle Vaccine Against COVID-19 Infection. Authorea. https://doi.org/10.22541/au.162615692.26217047/v2
• Zeng, C., Zhang, C., Walker, P. G., & Dong, Y. (2020). Formulation and Delivery Technologies for mRNA Vaccines. In Current Topics in Microbiology and Immunology (pp. 1–40). https://doi.org/10.1007/82_2020_217
• Zhang, C., Maruggi, G., Shan, H., & Li, J., (2019). Advances in mRNA Vaccines for Infectious Diseases. Frontiers in Immunology, 10(MAR), 1–13. https://doi.org/10.3389/fimmu.2019.00594
• Zhao, M., Vandersluis, M., Stout, J., Haupts, U., Sanders, M., & Jacquemart, R. (2019). Affinity chromatography for vaccines manufacturing: Finally ready for prime time? Vaccine, 37(36), 5491–5503. https://doi.org/10.1016/j.vaccine.2018.02.090
• Zhao, Q., Gao, Y., Xiao, M., Huang, X., & Wu, X. (2021). Synthesis and immunological evaluation of synthetic peptide based anti-SARS-CoV-2 vaccine candidates. Chem Commun (Camb),15;57 (12): 1474-1477. doi: 10.1039/d0cc08265a.
• Борисович, Р. А., Александрович, Р. Е., Поликарповна, Б. М., Васильевна, Г. Е., Дмитриевна, Д. Е., Рамисович, И. И., ve diğerleri (2021). Peptide immunogens and a vaccine composition against coronavirus infection covid-19 using peptide immunogens, RU2738081C1.